We have collected information about Rnai Delivery for you. Follow the links to find out details on Rnai Delivery.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977003/
Jun 11, 2010 · The site of action of siRNA therapeutics is the cytosol. The barriers to siRNA delivery are multiple and depend on the targeted organs and the administration routes. In general, locoregional delivery of siRNA has fewer barriers compared to systemic delivery.Author: Jie Wang, Ze Lu, M. Guillaume Wientjes, Jessie L.-S. Au
https://www.alliedacademies.org/articles/rethinking-delivery-viral-vectors-and-rna-interference-7646.html
More recently developed vector systems have excellent safety profiles as a result of systematic improvements in this key area. The time has come to re-consider viral vectors in order to overcome the complications and allow efficient, specific and well-tolerated delivery in RNAi applications.Author: Jens Kurreck
https://www.ncbi.nlm.nih.gov/pubmed/29243000
Effective delivery systems are essential to enable the full therapeutic potential of RNAi. An ideal nanocarrier not only addresses the challenges of delivering naked siRNA/miRNA, including its chemically unstable features, extracellular and intracellular barriers, and innate immune stimulation, but also offers "smart" targeted delivery.Author: Xiuhui Chen, Xiuhui Chen, Lingegowda S. Mangala, Cristian Rodriguez-Aguayo, Xianchao Kong, Gabriel L...
https://www.sciencedirect.com/science/article/pii/S0142961216302782
To develop RNA-based therapeutics, it is crucial to create delivery vectors that transport the RNA molecule into the cell cytoplasm. Naturally released exosomes vesicles (also called “Extracellular Vesicles”) have been proposed as possible RNAi carriers, …Author: Taral R. Lunavat, Su Chul Jang, Su Chul Jang, Lisa Nilsson, Hyun Taek Park, Gabriela Repiska, Cecili...
https://www.sciencedirect.com/science/article/pii/S0168365914005677
2.8. RNAi delivery strategies employed in the current clinical pipeline. The evolution of the RNAi clinical pipeline reflects the aforementioned advantages of systemic over local RNAi delivery. Just 3 years following the discovery of RNAi occurring in mammalian cells , in 2004 the first RNAi therapeutics candidate entered clinical development ...Author: D. Haussecker
http://altogenlabs.com/rna-interference-rnai-services/in-vivo-sirna-delivery-and-tissue-targeting/
In Vivo siRNA Delivery and Tissue Targeting (In Vivo RNAi) In Vivo siRNA Delivery and Tissue Targeting. RNAi-induced gene silencing is used to study gene function in cultured cells (in vitro).Most often, these effects are induced by the introduction of small-interfering RNA (siRNA) or microRNA (miRNA).
https://www.nature.com/articles/d41586-019-03071-9
Oct 16, 2019 · Delivery has been such a significant challenge that those working in the area of RNAi therapeutics might be forgiven for admitting defeat. And there’s …Author: Bianca Nogrady
https://investors.alnylam.com/press-release?id=24656
Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19. Mar 04, 2020 — Recent Alnylam advances in lung delivery technology suggest possible utility of siRNAs in targeting SARS-CoV-2 and other coronaviruses — Vir to lead development of potential coronavirus RNAi therapeutic candidates, with Alnylam retaining an option ...
Searching for Rnai Delivery?
You can just click the links above. The data is collected for you.
